A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors
Latest Information Update: 06 Sep 2023
At a glance
- Drugs Brontictuzumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors OncoMed Pharmaceuticals
- 06 Dec 2016 Results of safety and preliminanary efficacy (n=23) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 16 Sep 2016 Status changed from recruiting to completed.
- 26 Feb 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017 as per ClinicalTrials.gov record.